Last reviewed · How we verify
BERDAZIMER SODIUM
At a glance
| Generic name | BERDAZIMER SODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2024 |
Approved indications
Common side effects
Key clinical trials
- P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne (PHASE3)
- P3 Study in Acne Comparing Once Daily SB204 and Vehicle (PHASE3)
- P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris (PHASE2)
- P3 Long Term Safety Study of Once Daily SB204 in Acne (PHASE3)
- A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum (PHASE2)
- Topical NVN1000 for the Treatment of External Genital and Perianal Warts (PHASE2)
- A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC (PHASE3)
- A Phase 3 Molluscum Contagiosum Efficacy and Safety Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BERDAZIMER SODIUM CI brief — competitive landscape report
- BERDAZIMER SODIUM updates RSS · CI watch RSS